The oral presentation and six posters to be shared at the ASH meeting
will review the results of pre-clinical and clinical research on the
pan-selectin antagonist, rivipansel, that
"We are delighted to have multiple abstracts accepted at ASH,
highlighting the success and breadth of our growing pipeline," said
Details of the data to be presented at ASH, including session times and locations, include:
Oral Presentation (submitted by Pfizer, Inc.)
Abstract #270-Rivipansel: A Small Pan-Selecting Antagonist Improves
Cerebral Perfusion and Inhibits Leukocyte Adhesion and in Murine Sickle
Cell Disease Model.
Posters (all poster sessions are in the
Abstract #4049--A Phase I/II Study of GMI¬1271, a Novel E¬Selectin
Antagonist, in Combination with Induction Chemotherapy in
Relapsed/Refractory and Elderly Previously Untreated Acute Myeloid
Leukemia; Results to Date.
Abstract #3826--E¬Selectin Antagonist GMI¬1271 Shows a Favorable Safety,
PK and Bleeding Profile in Phase I Studies of
Abstract #2823--Vascular E-Selectin Protects Leukemia Cells from
Chemotherapy By Directly Activating Pro-Survival NF-Kb Signaling -
Therapeutic Blockade of E-Selectin Dampens NF-Kb Activation.
Abstract #3519—Dual E-Selectin/CXCR4 Antagonist GMI-1359 Exerts
Efficient Anti-Leukemia Effects in a FLT3 ITD Mutated Acute Myeloid
Leukemia Patient-Derived Xenograph Murine Model.
Abstract #2826—Administration of the Dual E-Selectin/CXCR4 Antagonist,
GMI-1359, Results in a Unique Profile of Tumor Mobilization from the
Bone Marrow and Facilitation of Chemotherapy in a Murine Model of FLT3
Abstract #2509--Rivipansel (GMI-1070) Inhibits E-Selectin Recognition of
Sialyl LewisX Activation and Arrest of Human Neutrophils Expressed on
CD62L (L-selectin) and Blocks Integrin.
The meeting abstracts are available at ASH's website.
This press release contains forward-looking statements regarding
GlycoMimetics' planned activities with respect to the clinical
development of its drug candidates, rivipansel, GMI-1271 and GMI-1359.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important factors,
including the availability and timing of data from ongoing clinical
trials, the uncertainties inherent in the initiation of future clinical
trials, whether interim results from a clinical trial will be predictive
of the final results of the trial or results of early clinical trials
will be indicative of the results of future trials, expectations for
regulatory approvals, availability of funding sufficient for
GlycoMimetics' foreseeable and unforeseeable operating expenses and
capital expenditure requirements, other matters that could affect the
availability or commercial potential of GlycoMimetics' drug candidates
and other factors discussed in the "Risk Factors" section of
GlycoMimetics' Annual Report on Form 10-K that was filed with the
News Provided by Acquire Media